ArticleThe Lancet. Oncology2025
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Swaminathan P Iyer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
65 papers cite itlatest 60 shown
this paperpooled ittrialcites it